Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 1/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2652439 | 0.82 | ADRB2 (0.44) | KHKTRPV4XDHADRB2ADRB1 | |
| SCHEMBL29824357 | 0.80 | KHK (0.36) | KHKTRPV4KDM4EMEN1KMT2A | |
| SCHEMBL30937561 | 0.78 | ALDH1A1 (0.36) | KHKTRPV4XDHADRB2ADRB1 | |
| SCHEMBL793224 | 0.78 | KHK (0.43) | KHKTRPV4XDHADRB2ADRB1 | |
| SCHEMBL29125383 | 0.78 | KHK (0.35) | KHKTRPV4KDM4EMEN1KMT2A | |
| SCHEMBL29802422 | 0.74 | VCAM1 (0.35) | KHKXDHKDM4EMEN1KMT2A | |
| SCHEMBL15812540 | 0.74 | VCAM1 (0.35) | KHKXDHKDM4EMEN1KMT2A | |
| SCHEMBL15633498 | 0.74 | ALDH1A1 (0.49) | KDM4EMAPTALDH1A1USP2 | |
| SCHEMBL29039316 | 0.74 | KDM4E (0.41) | KHKKDM4ECYP11B1CYP11B2MAPT | |
| SCHEMBL7951303 | 0.73 | KDM4E (0.38) | KHKXDHADRB2ADRB1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023083365-A1 | PAD4 INHIBITORS AND USE THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2023-05-19 | — | — | WO | disclosed |
| CN-104961723-A | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBOTT LAB | 2015-10-07 | — | — | CN | disclosed |
| CN-101155797-B | 1H-benzimidazole-4-carboxamide compounds substituted at the 2-position with a quaternary carbon atom are potent PARP inhibitors | ABBOTT LAB | 2015-04-29 | — | — | CN | disclosed |
| EP-2420234-B1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION AS PARP INHIBITORS FOR USE IN TREATING CANCER | ABBOTT LAB (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2420499-B1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION AS POTENT PARP INHIBITORS | ABBOTT LAB (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-1869011-B1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LAB (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2420234-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position as PARP inhibitors for use in treating cancer | Abbott Laboratories (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-2420499-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position as potent PARP inhibitors | Abbott Laboratories (US) | 2012-02-22 | — | — | EP | disclosed |
| US-7550603-B2 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBOTT LABORATORIES INC. (US) | 2009-06-23 | — | — | US | disclosed |
| CN-101155797-A | 1H-benzimidazole-4-carboxamide compounds substituted at the 2-position with a quaternary carbon atom are potent PARP inhibitors | ABBOTT LAB (US) | 2008-04-02 | — | — | CN | disclosed |
| EP-1869011-A2 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006110816-A2 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBVIE INC. | 2006-10-12 | — | — | US | disclosed |
| EP-1244615-A1 | METHOD FOR PRODUCING N-SUBSTITUTED 2,4-DIAMINO-5-FLUORO BENZONITRILES AND NOVEL INTERMEDIATES | Bayer Aktiengesellschaft (DE) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001047873-A1 | METHOD FOR PRODUCING N-SUBSTITUTED 2,4-DIAMINO-5-FLUORO BENZONITRILES AND NOVEL INTERMEDIATES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | PARP1, PARP2, PARP4 | KHK 2201/4885TRPV4 4777/4885XDH 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.